Online inquiry

IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4684MR)

This product GTTS-WQ4684MR is a type of mRNA modified with 5-Methyl-CTP & Pseudo-UTP, which ecodes the monoclonal antibody that targets MSTN gene. The antibody can be applied in Duchenne muscular dystrophy (DMD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005259.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2660
UniProt ID O14793
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4684MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ5048MR IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CA Exendin-4
GTTS-WQ1048MR IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-621
GTTS-WQ1304MR IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABT-555
GTTS-WQ13641MR IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA R4930
GTTS-WQ8381MR IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA aTROP2S7
GTTS-WQ5679MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CDX-011 (DOX)
GTTS-WQ9278MR IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMMU-132
GTTS-WQ1171MR IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABP 501
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW